Sichuan Science and Technology Innovation Investment Group
四川科创投集团
Sichuan Science and Technology Innovation Investment Group (四川科创投集团) is a state-backed investment fund that appears in elsewhere's corpus primarily as a repeat investor in biotech and deep-tech startups. The fund was a continuing backer in Zenitar's (赜灵生物) nearly RMB 600 million Series C round in early 2026, alongside institutions such as 5Y Capital, Huajin Capital, and Guosheng Capital . The same funding round was led by Temasek's Fullerton Capital and Qiming Venture Partners, with follow-on participation from Tencent Investment, BlueRun Ventures, and others .
elsewhere's corpus does not cover the fund's founding date, AUM, or mandate beyond this single disclosed position.
AI-generated — may contain errors, please verify.
Coverage
New Forces Keep Coming｜5Y News Monthly
The big news from last month.
BlueRun Ventures-backed Zenitar closes nearly RMB 600 million Series C round | BlueRun Family
Build a closed-loop, iterative system spanning "target identification — molecular design — efficacy validation"
5Y News | Zai Ling Bio Completes Nearly RMB 600 Million Series C Financing
The funding will go toward global clinical development, pipeline expansion, and technology platform upgrades.
